HNK-1 Antibody [CDLA57] | 33-948

HNK-1 Antibody [CDLA57] | 33-948 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: Recombinant human protein was used as the immunogen for the HNK-1 antibody.

Research Area: Immunology

Tested Application: IF, IHC-P

Application: Immunofluorescence: 0.5-1 ug/ml
Immunohistochemistry (FFPE) : 2-4 ug/ml for 30 min at RT (1)
Prediluted format : incubate for 30 min at RT (2)
Optimal dilution of the HNK-1 antibody should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 10-20 min followed by cooling at RT for 20 min
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required) , drip mAb solution onto the tissue section and incubate at RT for 30 min.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: PEG precipitation

Clonality: Monoclonal

Clone: CDLA57

Isotype: IgM, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1, Beta-1, 3-glucuronyltransferase 1, Glucuronosyltransferase P, GlcAT-P, UDP-GlcUA:glycoprotein beta-1, 3-glucuronyltransferase, GlcUAT-P, B3GAT1, GLCATP

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: CD57/HNK-1 marks a subset of lymphocytes known as natural killer (NK) cells. Follicular center cell lymphomas often contain many NK cells within the neoplastic follicles. Anti-CD57/HNK-1 also stains neuroendocrine cells and their derived tumors, including carcinoid tumor and medulloblastoma. Anti-CD57/HNK-1 can also be useful in separating type B3 thymoma from thymic carcinoma when combined with a panel that includes antibodies against GLUT1, CD5, and CEA.